Centiva Capital LP Makes New $543,000 Investment in STAAR Surgical (NASDAQ:STAA)

Centiva Capital LP acquired a new stake in STAAR Surgical (NASDAQ:STAA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,368 shares of the medical instruments supplier's stock, valued at approximately $543,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical in the 4th quarter valued at $180,000. Bridgefront Capital LLC lifted its holdings in STAAR Surgical by 27.2% during the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock worth $262,000 after buying an additional 2,306 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of STAAR Surgical in the 4th quarter valued at about $278,000. Y Intercept Hong Kong Ltd acquired a new stake in STAAR Surgical during the 4th quarter worth $292,000. Finally, Counterpoint Mutual Funds LLC bought a new position in STAAR Surgical during the fourth quarter worth about $298,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Piper Sandler dropped their price objective on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. Wells Fargo & Company began coverage on shares of STAAR Surgical in a research note on Monday, April 21st. They issued an "equal weight" rating and a $17.00 target price for the company. Jefferies Financial Group downgraded shares of STAAR Surgical from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus cut their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $24.63.

STAAR Surgical Stock Up 5.2%

STAAR Surgical stock traded up $0.91 during trading on Thursday, hitting $18.34. The stock had a trading volume of 288,447 shares, compared to its average volume of 811,681. The stock's 50 day moving average is $17.61 and its two-hundred day moving average is $21.74. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $49.86. The stock has a market cap of $908.50 million, a price-to-earnings ratio of -44.80 and a beta of 0.65.

Insider Activity

In other news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68. Following the purchase, the insider now owns 11,289,437 shares of the company's stock, valued at approximately $174,873,379.13. The trade was a 0.32% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 1,482,965 shares of company stock valued at $24,523,688 in the last 90 days. Insiders own 1.00% of the company's stock.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.